Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Optimal Pubertal Inductio… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

Artikel i vetenskaplig tidskrift
Författare M. Donaldson
B. Kristrom
Carina Ankarberg-Lindgren
S. Verlinde
J. van Alfen-van der Velden
A. Gawlik
Mmhj van Gelder
T. Sas
M. Agota
N. Akulevich
K. Albertsson-Wikland
C. Ankarberg-Lindgren
E. Bober
A. Buyukgebiz
J. C. Carel
C. Dacou-Voutetakis
S. D. Keizer-Schrama
M. Donaldson
E. J. Gault
L. Ghizzoni
C. Kanaka-Gantenbein
A. Gawlik
B. Kristrom
A. Kurtev
E. Malecka-Tendera
L. Mazzanti
E. Norjavaara
J. Popovic
M. Ranke
T. Sas
A. Sallai
S. Stagi
J. van Alfen-van der Velden
S. Verlinde
M. Wasniewska
D. Zenaty
N. Zuckerman-Levin
Endocrinology European Soc Paediat
Publicerad i Hormone Research in Paediatrics
Volym 91
Nummer/häfte 3
Sidor 153-163
ISSN 1663-2818
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Sidor 153-163
Språk en
Länkar dx.doi.org/10.1159/000500050
Ämnesord Turner syndrome, Puberty, 17 beta-estradiol, Oral induction, Transdermal induction, sex steroid replacement, growth-hormone, women, management, secretion, Endocrinology & Metabolism, Pediatrics
Ämneskategorier Pediatrik

Sammanfattning

Background: Most girls with Turner syndrome (TS) require pubertal induction with estrogen, followed by long term replacement. However, no adequately powered prospective studies comparing transdermal with oral 17 beta-estradiol administration exist. This reflects the difficulty of securing funding to study a rare condition with relatively low morbidity/mortality when competing against conditions such as cancer and vascular disease. Protocol Consensus: The TS Working Group of the European Society for Paediatric Endocrinology (ESPE) has agreed to both a 3-year oral and a 3-year transdermal regimen for pubertal induction. Prerequisites include suitable 17 beta-estradiol tablets and matrix patches to allow the delivery of incremental doses based on body weight. Study Proposal: An international prospective cohort study with single centre analysis is proposed in which clinicians and families are invited to choose either of the agreed regimens, usually starting at 11 years. We hypothesise that pubertal induction with transdermal estradiol will result in better outcomes for some key parameters. The primary outcome measure chosen is height gain during the induction period. Analysis: Assessment of the demographics and drop-out rates of patients choosing either oral or transdermal preparations; and appropriate analysis of outcomes including pubertal height gain, final height, liver enzyme and lipid profile, adherence/acceptability, cardiovascular health, including systolic and diastolic blood pressure and aortic root diameter and bone health. Conclusion: The proposed model of prospective data collection according to internationally agreed protocols aims to break the current impasse in obtaining evidence-based management for TS and could be applied to other rare paediatric endocrine conditions. (C) 2019 S. Karger AG, Basel

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?